生命科学资讯

Novo Nordisk’s ‘strategic conundrum’: How being anchored to the past could cost it the future

Novo Nordisk inks $2.1B pact with Langer startup to boost oral drug delivery prowess

Novo Nordisk teams with Langer-founded biotech for oral obesity drugs

Novo Nordisk to slash Wegovy list price in half in 2027

Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market

Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial

Novo Nordisk to expand Irish factory for Wegovy pill

Novo Nordisk sues Hims over Wegovy patent infringement, considers seeking 'hundreds of millions' in damages

Embattled Novo Nordisk considers buying a monthly GLP-1 to bolster portfolio

With 200 JPM meetings, Novo Nordisk BD head searches for the next Metsera

Novo Nordisk offloads diabetes assets to Aspect amid cell therapy retreat

Novo Nordisk, BioMarin make AI moves; Bristol Myers welcomes neurology exec from Eisai

A compounding pharmacy hits back at Eli Lilly, Novo Nordisk with antitrust lawsuit

FDA to meet Novo Nordisk on troubled site; AbbVie buys drug-device factory

Novo Nordisk Foundation invests $860M in Danish institute nurturing homegrown biotechs

Novo Nordisk Foundation to inject $850M+ into BioInnovation Institute through 2035

#JPM26: Novo Nordisk CEO says pharma can learn from the GLP-1 compounding boom

Novo Nordisk launches Wegovy pill at $25 per month for insured patients, $149 cash

Novo Nordisk’s weight loss pill approved by FDA

Novo Nordisk eyes a strong launch with FDA approval of obesity pill